What do I need to do to get GLP-1 coverage?

In this portion of the Pharmaceutical Executive Video Interview, Jim Sheehan of Lowenstein Sandler, Chair of the FDA Division of Regulatory Affairs, discusses how the FDA and other regulators are likely to respond to growing public interest in GLP-1 drugs and their potential off-label uses, and what needs to be done to ensure GLP-1 is covered.